retatrutide phase 3 2025 triple agonist glp-1 gip glucagon Eli Lilly's shows promising weight loss results in trial Retatrutide, a TRIPLE agonist (GLP1,

Biosimilar semaglutide development programs have been announced by 14 manufacturers globally, including Samsung Bioepis , Biocon Biologics , Sandoz , Mylan and Viatris , Hikma , and multiple Chinese biotechnology companies

This is my opinion, based on the data we have at hand, so its a little bit hypothetical I think these amylin medications could emerge as a first-line treatment for obesity, Garvey said

Real-world GLP-1 RA therapy in type 2 diabetes: a long-term effectiveness observational study

Liu Y, Chen S, Zhen R

This integrative strategy could offer new avenues for managing treatment-resistant obesity-related OSAS

[DOI] [PMC free article] [PubMed] [Google Scholar] 40